/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Research To Practice | Oncology Videos
  2. Metastatic Bladder Cancer — Rapid Case Review Issue 7
Metastatic Bladder Cancer — Rapid Case Review Issue 7

Metastatic Bladder Cancer — Rapid Case Review Issue 7

Research To Practice | Oncology Videos · Sep 16, 2026

Experts discuss metastatic bladder cancer cases, covering EV-PEMBRO toxicity management, intermittent therapy, and emerging anti-HER2 agents.

Frame EV-PEMBRO Toxicity as a 'Marathon' to Ensure Patient Honesty on Side Effects

To prevent irreversible toxicities like neuropathy from enfortumab vedotin, clinicians should proactively set expectations. Emphasize that dose adjustments are normal and part of a long-term strategy. Framing it as a "marathon, not a sprint" encourages patients to report side effects early, rather than hiding them for fear of stopping treatment.

Metastatic Bladder Cancer — Rapid Case Review Issue 7 thumbnail

Metastatic Bladder Cancer — Rapid Case Review Issue 7

Research To Practice | Oncology Videos·2 months ago

Rule Out C. Diff and Pancreatitis Before Blaming Combination Therapy for Diarrhea

In bladder cancer patients on combination therapies like EV-PEMBRO, diarrhea should not be automatically attributed to treatment-related colitis. Clinicians must maintain a broad differential diagnosis, including common mimics like C. diff infection (due to frequent antibiotic use) and less common ones like pancreatitis, before escalating immunosuppression.

Metastatic Bladder Cancer — Rapid Case Review Issue 7 thumbnail

Metastatic Bladder Cancer — Rapid Case Review Issue 7

Research To Practice | Oncology Videos·2 months ago

Treat Bladder Cancer Patients With Immunotherapy Despite Well-Controlled Autoimmune Disease

A history of autoimmune disease, even one requiring treatment like methotrexate for rheumatoid arthritis, should not be an absolute contraindication for immune checkpoint inhibitors. In collaboration with specialists, patients with well-controlled psoriasis, IBD, or even multiple sclerosis can often safely receive immunotherapy and achieve prolonged responses.

Metastatic Bladder Cancer — Rapid Case Review Issue 7 thumbnail

Metastatic Bladder Cancer — Rapid Case Review Issue 7

Research To Practice | Oncology Videos·2 months ago

Low-Risk Bladder Cancer Can Metastasize Years Later Without Local Progression

Patients with non-muscle invasive bladder cancer, even after years of clear surveillance cystoscopies, can develop widespread metastatic disease de novo. This rare but real phenomenon questions the adequacy of current imaging surveillance guidelines for patients considered to have low-risk disease, suggesting a potential role for ctDNA.

Metastatic Bladder Cancer — Rapid Case Review Issue 7 thumbnail

Metastatic Bladder Cancer — Rapid Case Review Issue 7

Research To Practice | Oncology Videos·2 months ago

Stop Antibody-Drug Conjugates Immediately for Asymptomatic Pneumonitis, Unlike Immunotherapy

The management of treatment-induced pneumonitis differs significantly between drug classes. While clinicians may treat through low-grade pneumonitis from immune checkpoint inhibitors, the safest approach for antibody-drug conjugates (ADCs) like TDXD is to stop the drug immediately upon any radiographic evidence, even if the patient is asymptomatic.

Metastatic Bladder Cancer — Rapid Case Review Issue 7 thumbnail

Metastatic Bladder Cancer — Rapid Case Review Issue 7

Research To Practice | Oncology Videos·2 months ago